GLOBAL HUMAN MICROBIOME MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL HUMAN MICROBIOME MARKET FORECAST 2018-2026

GLOBAL HUMAN MICROBIOME MARKET FORECAST 2018-2026

The Global Human Microbiome Market is anticipated to grow at a CAGR of 22.41% between 2022 and 2026. The human microbiome represents a significant commercial opportunity for the life sciences sector. A wide range of scientific studies have clearly demonstrated the role of the microbiome in the pathogenesis of a variety of mainstream diseases.

GLOBAL HUMAN MICROBIOME MARKET FORECAST 2018-2026

Global Human Microbiome Market by Applications (Drugs, Diagnostics) by Products (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs, Other Products) by Diseases (Cancer, Obesity, Type 2 Diabetes, Ulcerative Colitis, Crohn’s Disease, Difficle Infection, Lactose Intolerance, Dental Caries, Recurrent Bacterial Vaginosis and Uti, Skin Disorders, Hyperoxaluria, Celiac Disease, Urea Cycle Disorder, Phenylketonuria, Non-alcoholic Steatohepatitishepatic Encephalopathy) & by Geography.

Request free sample

The Global Human Microbiome Market is anticipated to grow at a CAGR of 22.41% between 2022 and 2026. The human microbiome represents a significant commercial opportunity for the life sciences sector. A wide range of scientific studies have clearly demonstrated the role of the microbiome in the pathogenesis of a variety of mainstream diseases. The Human Microbiome market is primarily driven by the following factors:

  • Rising prevalence of precision medicines
  • Focus on early disease detection and diagnosis
  • Growing prevalence of chronic diseases

Global Human Microbiome Market

To know more about this report, request a free sample copy

The important driver increasing growth in the Global Human Microbiome Market is the rising prevalence of precision medicines. Precision medicine allows patients to enrich the effectiveness of the drug on patients. Precision medicine uses diagnostic tests to recognize specific medical treatments and procedures. These diagnostic tests are then joint with the individual’s medical records, values, and circumstances, which allow the doctors to develop targeted treatment and prevention plans.

The commercial role of microbiota in various diseases of Human Microbiome Market is used extensively for various diseases treatment. Recent research in microbiome field has indicated the role of commensal microbiota (e.g., yeast, fungi, bacteria) in the genesis and progression of cancer as well. Obesity is the single most important risk factor for atherosclerotic cardiovascular disease, type 2 diabetes, Alzheimer’s disease non-alcoholic fatty liver disease, and certain types of cancers. More than 500 million people across the world suffer from type 2 diabetes. Ulcerative colitis affects solitary colon, while the inflammatory configuration includes superficial inflammation commencement at the anal verge, encompassing proximally over the colon in an incessant method. Crohn’s disease affects several sections of the gastrointestinal tract (from the mouth to anus). Clostridium difficle is an obligate anaerobe bacterium that causes C. difficle infection, which affects the gastrointestinal tract. Lactose intolerance is a common gastrointestinal condition that often causes painful and embarrassing symptoms from the consumption of dairy products. Hepatic encephalopathy (HE) is a complication of hepatic cirrhosis.

Barriers to early detection and diagnosis and lack of technical expertise are the major factors hindering the Human microbiome market. One of the major barriers in the early detection and diagnosis of the disease is sample collection. For instance, collections of the faecal sample which are used to study gut microbiome. The research and training institutions for human microbiomes are substantially less.  Thus, lack of technical expertise required to assemble and study large-scale microbiome datasets is restraining the market growth of Global Human Microbiome Market.

The Global Human microbiome market segments include applications, products, and diseases.

Applications are segmented into:

  • Drugs
  • Diagnostics

Products are segmented into:

  • Probiotics
  • Foods
  • Prebiotics
  • Medical foods
  • Diagnostic device
  • Drugs
  • Other products

Diseases are segmented into:

  • Cancer
  • Obesity
  • Type 2 diabetes
  • Ulcerative colitis
  • Crohn’s disease
  • Difficle infection
  • Lactose intolerance
  • Dental caries
  • Recurrent bacterial vaginosis and UTI
  • Skin disorders
  • Hyperoxaluria
  • Celiac disease
  • Urea cycle disorder
  • Phenylketonuria
  • Non-alcoholic steatohepatitis
  • Hepatic encephalopathy

This report covers the present market conditions and the growth prospects of the Global Human Microbiomes Market for 2018-2026 and considered the revenue generated through the sales of Human microbiomes for applications, products, and diseases to calculate the market size, by considering 2017 as the base year.

Geographically, the global Human microbiomes market has been segmented on the basis of four major regions, which include:

  • North America: The U.S. & Canada
  • Asia-Pacific: China, India, Japan, South Korea, Australia & Rest of APAC
  • Europe: The UK, France, Germany, Italy, Spain & Rest of Europe
  • Rest of World: Latin America & Middle East and Africa

The Human microbiome market in North America is expected to hold the largest share by 2026 on account of the growing funding and research and development activities by companies and research institutes. The United States is a major country in the North American human microbiome market. The presence of a large number of players who are adopting various initiatives such as investment in research and development for the development of the new therapeutic area for microbiome to prevent health issues such as irritable bowel syndrome, immune diseases, etc. is further contributing to the market. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Human microbiome market. Human microbiome in on a surging trend in the Asia-Pacific region owing to rising government funding in precision medicine and the emergence of numerous initiatives to develop human microbiome in countries such as China, Japan. These initiatives aim to optimize the methods for the assessment of the effect of the gut microbiome on human health through the standardization of protocols and procedures.

The Human microbiome market is segmented on the basis of Applications which are sub-divided into Drugs & Diagnostics and also is also segmented on the basis of Products which are sub-divided into Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs & other products. Microbiome in Drugs helps in the development of novel non-prescription therapies that have the ability to improve the health status of the person by networking with the human microbiome in particular ways. Microbiomes are majorly used to measure and detect the concentration of biomarkers substances in the blood such as glucose, cholesterol, creatine kinase, cortisol, etc. that can help detect infection or disease. Probiotics are live microorganisms that include bacteria and yeast, which are good for health, especially for the digestive system. Prebiotic refers to a specialized plant fibre that positively nurtures the good bacteria that are already present in the colon of the large bowel. Microbiota or microbiome plays a significant role in the effectiveness of therapeutic compounds. It provides a major source of reductive metabolizing capability.

The major market players in the GLOBAL HUMAN MICROBIOME market are:

  • AVIDBIOTICS INC.
  • AVIDBIOTICS CORP.
  • MICROBIOME THERAPEUTICS
  • REBIOTIX
  • 4D PHARMA

Company Profiles covers analysis of important players.

AvidBiotics is a privately held company developing a portfolio of therapeutic proteins targeting bacterial diseases and cancer. AvidBiotics has two platforms for the development of protein therapeutics: Avidocin proteins & MicAbody proteins. Another company, 4D Pharma,  is a U.K.-based company founded in 2014 that is developing a class of molecules called live biotherapeutics. Live biotherapeutics are strains of gut commensal bacteria that are isolated from healthy human donors.

Key Findings of the Global Human microbiome market:

  • North America is the global leader in human microbiome market
  • Probiotics product are majorly used
  • Usage of personalized medicines is increasing
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • NORTH AMERICA IS THE GLOBAL LEADER IN HUMAN MICROBIOME MARKET
      • PROBIOTICS PRODUCT ARE MAJORLY USED
      • USE OF PERSONALIZED MEDICINES IS INCREASING
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • RISING PREVALENCE OF PRECISION MEDICINES
      • FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS
      • GROWING PREVALENCE OF CHRONIC DISEASES
    • MARKET RESTRAINTS
      • BARRIERS IN EARLY DETECTION AND DIAGNOSIS
      • LACK OF TECHNOLOGICAL EXPERTISE
      • LACK OF SKILLED PROFESSIONALS AND LACK OF PROPER INFRASTRUCTURE IN MICROBIOME STREAM
      • STRINGENT GOVERNMENT REGULATIONS
    • MARKET OPPORTUNITIES
      • INCREASING INVESTMENT IN NOVEL DRUGS
      • GROWING INVESTMENT IN R&D
      • INCREASE IN LIFESTYLE DISEASES ARE EXPECTED TO DRIVE THE DEMAND FOR NEW AND ADVANCED DRUGS
      • RAPIDLY CHANGING LIFESTYLE IN THE EMERGING COUNTRIES
    • MARKET CHALLENGES
      • LACK OF AWARENESS
      • NEW TECHNOLOGY BARRIER TO ENTER INTO THE MARKET
  1. MARKET SEGMENTATION
    • MARKET BY APPLICATIONS 2018-2026
      • DRUGS
      • DIAGNOSTICS
    • MARKET BY PRODUCTS 2018-2026
      • PROBIOTICS
      • FOODS
      • PREBIOTICS
      • MEDICAL FOODS
      • DIAGNOSTIC DEVICE
      • DRUGS
      • OTHER PRODUCTS
    • MARKET BY DISEASES 2018-2026
      • CANCER
      • OBESITY
      • TYPE 2 DIABETES
      • ULCERATIVE COLITIS
      • CROHN’S DISEASE
      • DIFFICLE INFECTION
      • LACTOSE INTOLERANCE
      • DENTAL CARIES
      • RECURRENT BACTERIAL VAGINOSIS AND UTI
      • SKIN DISORDERS
      • HYPEROXALURIA
      • CELIAC DISEASE
      • UREA CYCLE DISORDER
      • PHENYLKETONURIA
      • NON-ALCOHOLIC STEATOHEPATITIS
      • HEPATIC ENCEPHALOPATHY
  1. KEY ANALYTICS
    • PORTER’S 5 FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIER
      • INTENSITY OF COMPETITIVE RIVALRY
    • ADVANCES IN MICROBIOME RESEARCH
    • AREA OF FOCUS FOR MICROBIOME BASED DRUGS AND DIAGNOSTICS
    • SUPPLY CHAIN ANALYSIS
    • KEY BUYING CRITERIA
    • REGULATORY FRAMEWORK
    • PRODUCT DEVELOPMENT STRATEGIES
    • ESTIMATION ANALYSIS
    • CHALLENGES IN MICROBIOME DRUG DEVELOPMENT
    • PARENT MARKET ANALYSIS
    • PRODUCTS IN PIPELINE
    • INTELLECTUAL PROPERTY, INVESTMENTS AND COLLABORATIONS
      • INTELLECTUAL PROPERTY
      • INVESTMENTS AND COLLABORATIONS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
    • 4D PHARMA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
    • AVIDBIOTICS INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
    • ACTOGENIX NV (ACQUIRED BY INTREXON CORPORATION)
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • AVIDBIOTICS CORP.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ENTEROME SA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • METABIOMICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC MOVES
    • MICROBIOME THERAPEUTICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC MOVES
    • METABOGEN AB
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • MIOMICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • OSEL INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • REBIOTIX
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • RITTER PHARMACEUTICALS, INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SECOND GENOME
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SYMBERIX INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • SYMBIOTIX BIOTHERAPIES, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • VEDANTA BIOSCIENCES, INC.(ACQUIRED BY PURETECH HEALTH PLC)
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES

 

TABLE LIST

TABLE 1       GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 2       GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 3       INCIDENCE OF DIABETES IN THE MAJOR COUNTRIES IN 2016(MILLIONS)

TABLE 4       COMPANIES WORKING TOWARDS DEVELOPING NEW DRUGS

TABLE 5       GLOBAL HUMAN MICROBIOME MARKET BY APPLICATIONS 2018-2022 ($ MILLION)

TABLE 6       GLOBAL HUMAN MICROBIOME MARKET BY APPLICATIONS 2022-2026 ($ MILLION)

TABLE 7       GLOBAL HUMAN MICROBIOME MARKET BY PRODUCTS 2018-2022 ($ MILLION)

TABLE 8       GLOBAL HUMAN MICROBIOME MARKET BY PRODUCTS 2022-2026 ($ MILLION)

TABLE 9       GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 10     GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 11     GLOBAL HUMAN MICROBIOME MARKET IN FOODS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 12     GLOBAL HUMAN MICROBIOME MARKET IN FOODS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 13     GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 14     GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 15     GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 16     GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 17     GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 18     GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 19     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 20     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 21     GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 22     GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 23     GLOBAL HUMAN MICROBIOME MARKET BY DISEASES 2018-2022 ($ MILLION)

TABLE 24     GLOBAL HUMAN MICROBIOME MARKET BY DISEASES 2022-2026 ($ MILLION)

TABLE 25     MICROBIOTA ASSOCIATED WITH CANCERS

TABLE 26     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CANCER

TABLE 27     MICROBIOTA ASSOCIATED WITH OBESITY

TABLE 28     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR OBESITY

TABLE 29     MICROBIOTA ASSOCIATED WITH TYPE 2 DIABETES

TABLE 30     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR TYPE 2 DIABETES

TABLE 31     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR ULCERATIVE COLITIS

TABLE 32     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CROHN’S DISEASE

TABLE 33     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE 34     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE 35     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE 36     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR RECURRENT BACTERIAL VAGINOSIS AND URINARY TRACT INFECTION

TABLE 37     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR SKIN DISEASES

TABLE 38     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR SKIN DISEASES

TABLE 39     MICROBIOTA ASSOCIATED WITH CELIAC DISEASE

TABLE 40     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CELIAC DISEASE

TABLE 41     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR UREA CYCLE DISORDER

TABLE 42     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR NON-ALCOHOLIC STEATOHEPATITIS

TABLE 43     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR HEPATIC ENCEPHALOPATHY

TABLE 44     FOCUS AREAS FOR MICROBIOME RESEARCH OF SPECIFIC DISEASES

TABLE 45     MICROBIOME DRUG DEVELOPMENT APPROACHES

TABLE 46     INVESTMENTS IN MICROBIOLOGY

TABLE 47     U.S. PATENTS FOR C. DIFFICLE INFECTION

TABLE 48     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR IRRITABLE BOWEL SYNDROME

TABLE 49     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR DIABETES AND OBESITY

TABLE 50     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR CANCER

TABLE 51     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR UREA CYCLE DISORDERS

TABLE 52     VENTURE CAPITAL INVESTMENTS IN MICROBIOME START-UPS ($ MILLIONS)

TABLE 53     INDUSTRY COLLABORATIONS IN MICROBIOME-BASED COMPANIES ($ MILLIONS)

TABLE 54     GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 55     GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 56     NORTH AMERICA HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 57     NORTH AMERICA HUMAN MICROBIOME MARKET 2022-2026 ($ MILLION)

TABLE 58     COLLECTIVE PROGRAMS BY CIHR’S ON HUMAN MICROBIOME IN 2017

TABLE 59     EUROPE HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 60     EUROPE HUMAN MICROBIOME MARKET 2012-2026 ($ MILLION)

TABLE 61     ASIA PACIFIC HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 62     ASIA PACIFIC HUMAN MICROBIOME MARKET 2022-2026 ($ MILLION)

TABLE 63     REST OF WORLD HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 64     REST OF WORLD HUMAN MICROBIOME MARKET 2022-2026 ($ MILLION)

 

FIGURE LIST

FIGURE 1     GLOBAL HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 2     ESTIMATED NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN UNITED STATES

FIGURE 3     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2018-2026 ($ MILLION)

FIGURE 4     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2018-2026 ($ MILLION)

FIGURE 5     GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS 2018-2026 ($ MILLION)

FIGURE 6     GLOBAL HUMAN MICROBIOME MARKET IN FOODS 2018-2026 ($ MILLION)

FIGURE 7     GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS 2018-2026 ($ MILLION)

FIGURE 8     GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS 2018-2026 ($ MILLION)

FIGURE 9     GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE 2018-2026 ($ MILLION)

FIGURE 10   GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2018-2026 ($ MILLION)

FIGURE 11   GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS 2018-2026 ($ MILLION)

FIGURE 12   GLOBAL HUMAN MICROBIOME MARKET IN CANCER 2018-2026 ($ MILLION)

FIGURE 13   GLOBAL HUMAN MICROBIOME MARKET IN OBESITY 2018-2026 ($ MILLION)

FIGURE 14   GLOBAL HUMAN MICROBIOME MARKET IN TYPE 2 DIABETES 2018-2026 ($ MILLION)

FIGURE 15   GLOBAL HUMAN MICROBIOME MARKET IN ULCERATIVE COLITIS 2018-2026 ($ MILLION)

FIGURE 16   GLOBAL HUMAN MICROBIOME MARKET IN CROHN’S DISEASE 2018-2026 ($ MILLION)

FIGURE 17   GLOBAL HUMAN MICROBIOME MARKET IN C. DIFFICLE INFECTION 2018-2026 ($ MILLION)

FIGURE 18   GLOBAL HUMAN MICROBIOME MARKET IN LACTOSE INTOLERANCE 2018-2026 ($ MILLION)

FIGURE 19   GLOBAL HUMAN MICROBIOME MARKET IN DENTAL CARIES 2018-2026 ($ MILLION)

FIGURE 20   GLOBAL HUMAN MICROBIOME MARKET IN RECURRENT BACTERIAL VAGINOSIS AND UTI  2018-2026 ($ MILLION)

FIGURE 21   GLOBAL HUMAN MICROBIOME MARKET IN SKIN DISORDERS 2018-2026 ($ MILLION)

FIGURE 22   MICROBES INVOLVED IN HEALTHY FACIAL SKIN (PERCENT MICROBES)

FIGURE 23   GLOBAL HUMAN MICROBIOME MARKET IN HYPEROXALURIA 2018-2026 ($ MILLION)

FIGURE 24   GLOBAL HUMAN MICROBIOME MARKET IN CELIAC DISEASE 2018-2026 ($ MILLION)

FIGURE 25   GLOBAL HUMAN MICROBIOME MARKET IN UREA CYCLE DISORDER 2018-2026 ($ MILLION)

FIGURE 26   GLOBAL HUMAN MICROBIOME MARKET IN PHENYLKETONURIA 2018-2026 ($ MILLION)

FIGURE 27   GLOBAL HUMAN MICROBIOME MARKET IN NON-ALCOHOLIC STEATOHEPATITIS 2018-2026 ($ MILLION)

FIGURE 28   GLOBAL HUMAN MICROBIOME MARKET IN HEPATIC ENCEPHALOPATHY 2018-2026 ($ MILLION)

FIGURE 29   HEALTHCARE EXPENDITURE IN THE U.S. 2015-2025 (% OF GDP)

FIGURE 30   RESEARCH AND DEVELOPMENT SPENDING IN THE LIFE SCIENCE 2014-2016 ($ BILLION)

FIGURE 31   NUMBER OF PATENTS GRANTED FOR WORLDWIDE MICROBIOME-BASED DRUGS 2010-2017

FIGURE 32   NORTH AMERICA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 33   THE U.S. HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 34   CANADA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 35   EUROPE HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 36   THE UNITED KINGDOM HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 37   FRANCE HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 38   GERMANY HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 39   ITALY HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 40   SPAIN HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 41   REST OF EUROPE HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 42   ASIA PACIFIC HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 43   CHINA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 44   INDIA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 45   JAPAN HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 46   SOUTH KOREA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 47   AUSTRALIA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 48   REST OF APAC HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 49   REST OF WORLD HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 50   LATIN AMERICA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 51   MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 52   MARKET SHARE ANALYSIS OF GLOBAL HUMAN MICROBIOME MARKET 2017(%)

  1. MARKET SEGMENTATION
    • MARKET BY APPLICATIONS 2018-2026
      • DRUGS
      • DIAGNOSTICS
    • MARKET BY PRODUCTS 2018-2026
      • PROBIOTICS
      • FOODS
      • PREBIOTICS
      • MEDICAL FOODS
      • DIAGNOSTIC DEVICE
      • DRUGS
      • OTHER PRODUCTS
    • MARKET BY DISEASES 2018-2026
      • CANCER
      • OBESITY
      • TYPE 2 DIABETES
      • ULCERATIVE COLITIS
      • CROHN’S DISEASE
      • DIFFICLE INFECTION
      • LACTOSE INTOLERANCE
      • DENTAL CARIES
      • RECURRENT BACTERIAL VAGINOSIS AND UTI
      • SKIN DISORDERS
      • HYPEROXALURIA
      • CELIAC DISEASE
      • UREA CYCLE DISORDER
      • PHENYLKETONURIA
      • NON-ALCOHOLIC STEATOHEPATITIS
      • HEPATIC ENCEPHALOPATHY
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now